Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RCE.AX
Strong SellRecce Pharmaceuticals Ltd · Healthcare · Australia · $82M · Avg Vol: $23K/d
2
StockRankGet insider-trade alerts
Q
9
V
23
M
28
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Loading 1Y...
PRICE (1Y)+2.1%
SMA 50SMA 200
Close
$0.2633
RSI (14)
40.0
52W High
$0.523
From 52W High
0.5%
SCORE BREAKDOWN
Quality
9
ROIC
-322.6%1.5
ROE
—N/A
GP/Assets
-90.1%0.3
Op. Margin
-3813.5%4.2
FCF/Assets
-76.1%3.8
Piotroski
112.1
Int. Cover
-17.6x19.2
D/E Ratio
—N/A
Current Ratio
0.08x0.2
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-3.8x25.0
P/FCF
—N/A
P/B
-5.9x25.0
P/S
117.7x6.9
Div Yield
—N/A
Momentum
28
52W High %
50%23.1
RS 6M
-28%33.9
SMA 50/200
0.77x15.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+23%36.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$82M
P/E (Forward)
-4.4x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RCE.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RCE.AX | Recce Pharmaceuticals Ltd(you) | $82M | 2 | Strong Sell |
| PAR.AX | Paradigm Biopharmaceuticals Limited | $96M | 4 | Strong Sell |
| IMMP | Immutep Limited | $57M | 8 | Strong Sell |
| DXB.AX | Dimerix Limited | $133M | 9 | Strong Sell |
| BOT.AX | Botanix Pharmaceuticals Limited | $51M | 9 | Strong Sell |
| ALA.AX | Arovella Therapeutics Limited | $55M | 14 | Strong Sell |
| NYR.AX | Nyrada Inc. | $134M | 13 | Strong Sell |
| ILA.AX | Island Pharmaceuticals Limited | $99M | 19 | Strong Sell |
| ACW.AX | Actinogen Medical Limited | $117M | 18 | Strong Sell |
| OCC.AX | Orthocell Limited | $151M | 14 | Strong Sell |
Peer medians: ROE -25.5% · P/E 35.3x · Gross margin 61.1%